secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001437749-24-017293
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Q1 2024 cash $117.9M; IPO net proceeds $108M extend runway to 2027
----------------------------------------------------------------------------

- Cash and securities $117.9M at March 31; proforma cash (incl. IPO) $225.9M.
- R&D expenses $7.8M vs $3.6M YoY; increase driven by product candidate development.
- Completed IPO in April 2024; net proceeds $108.0M, extending cash runway to end of 2027.
- Initiated Phase 2 trial of PIPE-307 in RRMS; J&J partner plans Phase 2 in depression in 2024.
- Nominated third development candidate CTX-343 (LPA1R antagonist); IND submission expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924017293/0001437749-24-017293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924017293/cont20240417_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-017293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer